Safety, Tolerability and Pharmacodynamics of QAX028 Compared to Open-label Tiotropium Bromide and Placebo in Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD) Patients.

Inclusion Criteria: * Male or female patients aged 40-75 years with diagnosis of mild or moderate COPD * Current or X-smokers with a smoking history of \>10 pack-years. * Screening ipratropium post-bronchodilation FEV1 at 1 h post-dose will be greater than 50% of the normal predicted FEV1 value. Exclusion Criteria: * Patients who can not comply with the following washout periods for standard COPD treatments as follows should be excluded: * Short-acting bronchodilators * Long-acting bronchodilators * Inhaled steroids Other protocol-defined inclusion/exclusion criteria may apply.